< Back to previous page
Researcher
Fred Van Leuven
- Disciplines:Genetics, Systems biology, Medical imaging and therapy, Molecular and cell biology, Other paramedical sciences
Affiliations
- Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 9 of 9
- Influence of chronic oligemia on neurovascular defects and their relation to the onset and development of neurodegeneration: in vivo evaluation of neurovascular response capacity and metabolism in an Alzheimer mouse model.From1 Oct 2013 → 17 Sep 2019Funding: FWO fellowships
- Mechanisms underlying protein tau-mediated neurodegeneration: combining transgenic mouse models and AAV vectors.From1 Oct 2010 → 30 Sep 2014Funding: BOF - Concerted Research Project from 1994
- Differential analysis of the physiological functions of GSK-3a/b isozymes in brain in vivo.From1 Oct 2009 → 30 Jun 2010Funding: BOF - Other initiatives
- Development and validation of active and passive immunotherapy targeted at protein Tau in transgenic mouse models for Alzheimer's diseaseFrom1 Oct 2008 → 13 Sep 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Tau-based Mabs and Vaccines: development and pre-clinical assessment of diagnostic and therapeutic potential in transgenic models for Tauopathy & Alzheimer's disease.From1 Oct 2008 → 30 Sep 2012Funding: IOF - Industrial Research Fund
- NEURO.GSK3: GSK3 in neuronal plasticity and neurodegeneration: basic mechanisms and pre-clinical assessment.From1 Oct 2008 → 31 Dec 2011Funding: Health
- The physiological and pathological contribution of GSK3 isozymes in normal mice and transgenic Alzheimer mice models.From1 Sep 2008 → 1 Jan 2010Funding: Own budget, for example: patrimony, inscription fees, gifts
- Inter-relations of protein Tau, GSK3 and Nectin-3 in synaptic structure and plasticity in the hippocampus of mouse models for Alzheimer's diseaseFrom1 Feb 2008 → 28 Jun 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Analysis of adaptations of cytoskeleton, dendritic spines and synaptic plasticity in relation to physiological and pathological phosphorylation of protein tau in vivo.From1 Jan 2008 → 31 Dec 2011Funding: FWO research project
Publications
31 - 40 of 86
- BACE1 Levels Correlate With Phospho-Tau Levels In Human Cerebrospinal Fluid(2013)
Authors: Soraia Barão Lourenco Barao, Lujia Zhou, Kate Adamczuk, Fred Van Leuven, Xavier Bossuyt, Rik Vandenberghe, Bart De Strooper
Pages: 671 - 8 - Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy(2013)
Authors: Fred Van Leuven
- Glycogen synthase kinase-3beta affects size of dentate gyrus and species-typical behavioral tasks in transgenic and knockout mice(2013)
Authors: Fred Van Leuven
Pages: 46 - 50 - Glycogen synthase kinase-3β (GSK3β) expression in a mouse model of Alzheimer's disease: A light and electron microscopy study(2013)
Authors: Fred Van Leuven
Pages: 313 - 327 - Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase(2013)
Authors: Fred Van Leuven
- Tauopathy Differentially Affects Cell Adhesion Molecules in Mouse Brain: Early Down-Regulation of Nectin-3 in Stratum Lacunosum Moleculare(2013)
Authors: Fred Van Leuven
- Fractalkine activates the Nrf2 to modulate glial activation in response to Tau P301L: implications in Alzheimer's disease(2013)
Authors: Fred Van Leuven
Pages: 85 - 85 - GSK3 inhibition promotes lysosomal biogenesis and the autophagic degradation of the Amyloid-β Precursor Protein(2012)
Authors: Fred Van Leuven
Pages: 4410 - 4418 - Glycogen Synthase Kinase 3 Inhibition Promotes Lysosomal Biogenesis and Autophagic Degradation of the Amyloid-β Precursor Protein(2012)
Authors: Fred Van Leuven
Pages: 4410 - 4418 - Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/β-TrCP Axis(2012)
Authors: Fred Van Leuven
Pages: 3486 - 3499
Patents
1 - 10 of 10
- Humanized tau antibody (Inventor)
- Pharmaceutical composition (Inventor)
- Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising tau (Inventor)
- Antibodies to phosphorylated tau aggregates (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)
- Methods of diagnosing tau-protein-associated disease (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)
- Pharmaceutical composition (Inventor)
- ANTIBODIES RECOGNISING PHOSPHO-TAU (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)